Combinations of nifedipine (NIF) and atenolol (ATN) are used for the treatment of arterial hypertension. Dosages values different from those presented on the label of pharmaceuticals can significantly impact a consumer’s health. To control the quality of the pharmaceuticals effectively, a method for the simultaneous determination of these both drugs using an anodically pretreated boron-doped diamond electrode coupled to differential pulse voltammetry technique was developed. The influence of supporting electrolyte, pH and scan rate on the current response of these both antihypertensives was examined to select the optimum experimental conditions. It was found that NIF and ATN provided two well-shaped and reproducible oxidation peaks at 0.97 V and 1.36 V (vs. Ag/AgCl electrode), respectively, in TRIS buffer solution (pH 8.0). At optimized differential pulse voltammetric parameters, the current response of NIF and ATN was proportionally linear in the concentration range of 3.98–107 μmol L–1 and 1.99–47.2 μmol L–1, with detection limit of 0.612 and 0.999 μmol L−1, respectively. The proposed method was successfully applied in analysis of several commercial combined dosage forms, whose accuracy was attested by good agreement of the results (paired t test at a 95% confidence level) with those obtained using high performance liquid chromatography.